Sigma-Aldrich (Poole,Dorset,UK) LGC Standards(Teddington,Surrey,UK) 1 mg/ml Sigma-Aldrich Greyhound Chromatography(Brikenhead,UK) / Waters ACQUITY UPL

Similar documents
MS Xevo G2 Q-Tof ESI+ 1 2 / pm-4 00 am 2 00 am # am # am #3 / pm am am #4 0.8 kv 20 V MS E ev MS E MASSLYNX

1 WSV SIR m/z Analyte RT (Min) SIR m/z Cone voltage (V) Ascorbic Acid (C) Thiamine (B1) Nicotinic Acid (B3) Pyridoxal (

HILIC UPLC/MS UPLC LC/ MS LC/MS HPLC 2-4 HPLC 4,5 HILIC / HILIC 80 ACQUITY UPLC Xevo QTof MS ACQUITY BEH HILIC HILIC TOF ESI 1.7 µm BEH HILIC UPLC HIL

ソリッドコアUHPLCカラムとUHPLCシステム、質量分析計を利用した違法薬物の高速スクリーニング分析

LC LC ACQUITY UPLC H-Class ACQUITY UPLC CSH C mm 1.7 µm : THF/ 2/8 A 1 mm / 4/6 THF 2 mg/ml THF/ 2 THF 2 ACQUITY UPLC CSH C 18

Waters Sigma-Aldrich 1.0 mg/ml LC Waters Alliance HPLC ACQUITY UPLC H-Class Bio 30 cm Alliance HPLC UV ACQUITY UPLC TUV mm nm XBridge Protein B

2D-UPLC/MS Catalin Doneanu, Keith Fadgen, StJohn Skilton, Martha Stapels, and Weibin Chen Waters Corporation, Milford, MA, U.S. 4 5 HCP UPLC/MS E HCP

LC ACQUITY UPLC H-Class Bio TUV Sigma, mg/ml 0.01 N 276 nm μl 0.4 ml/min L g/l / 99% / 65/15/20 v/v/v 10% 10% 0.01 N ACQUITY

ACQUITY UPC 2 ACQUITY UPC 2 A A+D3 D ml E 10 ml K μm K μm PDA ACQUITY UPC 2 BEH mm, 1.7 μm ACQUITY UPC 2 HSS C 18 SB 3.

UPC 2 Baiba Cabovska, Michael D. Jones, and Andrew Aubin Waters Corporation, Milford, MA, USA UPC 2 ACQUITY UPC 2TM ACQUITY SQD Empower 3 UPC GC

LCMS14003:UHPLC-Orbitrap質量分析計による環境汚染物質のターゲット分析、ノンターゲット分析

low_ JAJP.qxd

[ OASIS SAMPLE-EXTRACTION PRODUCTS ] LC-MS HPLC UPLC 1

[ GLYCAN ANALYSIS SLUTINS ] [ GLYCAN ANALYSIS SLUTINS ] N N 3 2

LC/MS/MS によるフェノール類分析 日本ウォーターズ株式会社 2015 Waters Corporation 1 対象化合物 Cl HO HO HO フェノール 2- クロロフェノール (2-CPh) Cl 4-クロロフェノール (4-CPh) HO Cl HO Cl HO Cl Cl 2,4



MassHunter Workstation Agilent MassHunter Workstation MS Agilent TOF Q-TOF LC/MS LC/MS GC/MS ICP-MS Agilent MS * MassHunter Workstation LC/MS GC/MS IC

HPLC UPLC JP UPLC システムによる 注入回数 3000 回以上 のルーチン製剤分析の実現 分析スループットの向上と使用溶媒量の削減 分析効率の向上 日本薬局方 (JP) は 薬事法第 41 条第一項の規定に基づき医薬品の品質を適性に担保するための公的な規範書であり 多くの医薬品の分析

NewsLetter-No2

日歯雑誌(H22・7月号)HP用/p06‐16 クリニカル① 田崎

pera1会社概要n

[ cortecs columns ] 可能性の限界に挑戦するµm 以下の ソリッドコアパーティクルカラム

JAPAN MARKETING JOURNAL 111 Vol.28 No.32008

JAPAN MARKETING JOURNAL 113 Vol.29 No.12009

JAPAN MARKETING JOURNAL 110 Vol.28 No.22008

MassPREP Mix %TFA 0.1% mg/ml < 70%DFVGYGVKDFVGVGVK 0.1%TFA 0.1% 1 4 mg/ml 1 ml/min UV 20 µl/min MS LC ACQUITY UPLC H-Class Bio

食糧 その科学と技術 No.46( )

untitled

橡A PDF

Agilent RapidFire 365 ハイスループット質量分析システム 創薬プロセスを加速する HTS システムテクノロジー

2 (FDA) 1 1 A D E K 1 LC UV 15 HPLC 3.5 UHPLC Agilent 12 Infinity LC Agilent 12 Infinity (G1311B) Agilent 12 Infinity (G13E) Agilent 12 Infinity (G131

untitled

平成26年度 化学物質分析法開発報告書

untitled

DCR-PC300K/IPK

平成26年度 化学物質分析法開発報告書

Microsoft Word - 14_LCMS_アクリルアミド

ERS-7

平成26年度 化学物質分析法開発報告書

表紙/宮副 森 森 森 柴田 芦塚

JAPAN MARKETING JOURNAL 123 Vol.31 No.32012

JAPAN MARKETING JOURNAL 115 Vol.29 No.32010

JAPAN MARKETING JOURNAL 110 Vol.28 No.22008

薬物分析法の開発

JAJP.qxp

Japanese Journal of Pesticide Science 42(1): (2017)

: / FDA HBsAg HIV 1/2 HCV : QMS : 3.5% IgM () 1.0% H317 - H334 - : : :: : QMS Everolimus : 6.4% (II) H400 - H % SDS QMS EDTA (K 3 ) EDTA (K 2 )

Agilent OpenLAB CDS ChemStation OpenLAB CDS ChemStation Lab Advisor Secure Workstation Data Store OpenLAB ECM OpenLAB C A P T U R E A N A L Y Z E S H

aisatu.pdf

Sigma

Sigma

バイオ解析チーム教育セミナーMS04

Microsoft Word - 14_LCMS_アクリルアミド

JAPAN MARKETING JOURNAL 123 Vol.31 No.32012

Metabolomic Profiling_JA.qxp

2

表 1. HPLC/MS/MS MRM パラメータ 表 2. GC/MS/MS MRM パラメータ 表 1 に HPLC/MS/MS 法による MRM パラメータを示します 1 化合物に対し 定量用のトランジション 確認用のトランジションとコーン電圧を設定しています 表 2 には GC/MS/MS

…i…J…‹†QŁ\1/4

針葉樹の材種の鑑別

1

FMV-TEOシリーズ(2008年6月版)製品カタログ

PM9000C 開墾と据置作業を行われる方へ

JAJP.indd

本製品をご購入.indd

00_cover1_2.pm6

アプリケーションソフトウェアガイド PM2200C用

GPC/SEC

お客様の成功が ウォーターズのミッションです ウォーターズは世界中のヘルスケア 環境保護 食の安全 水質管理分野の発展に 貢献しています 未来につながる実用的な科学革新を提供しつづけることによって 研究開発に携わる企業や専門機関の成功に寄与いたします ウォーターズは豊かな経験を生かし 研究に携わるお

筆王 for NEC

2 3

JAMSTEC Rep. Res. Dev., Volume 12, March 2011, 27 _ 35 1,2* Pb 210 Pb 214 Pb MCA 210 Pb MCA MCA 210 Pb 214 Pb * 2

1

+08APSアンダーソンカタログ.indd

<4D F736F F D F90858C6E5F C B B B838B>

ドコモP-01Hカタログ



Made for Life Report 2008

Microsoft Outlook 2013

憲法とは何か


<4D F736F F D C6E30385F A B B83932E444F43>

30% OFF & 31 Eppendorf TC 30% OFF Cell Imaging Dishes 145/170 µm Cell Imaging Coverglasses & Slides 1/2/4/8 chamber > 2 mm 750 µl > 170 µm 145 µ

JP.qxd

SEC (SEC) SEC SEC SEC 2

☆H23 13-農薬一斉分析(大垣).doc




JAJP.indd

Katrin Strassburg, 1,2 Billy Joe Molloy, 5 Claude Mallet, 3 André Duesterloh, 4 Igor Bendik, 4 Thomas Hankemeier, 1,2 James Langridge, 5 Rob J. Vreeke


01

1

Stepwise Chow Test * Chow Test Chow Test Stepwise Chow Test Stepwise Chow Test Stepwise Chow Test Riddell Riddell first step second step sub-step Step

PALL NEWS vol.126 November 2017

1 No.236 HP TAXUS

JST05-11.indd

,276 3,

Transcription:

ACQUITY UPLC I-Class/Xevo TQD Mark Roberts and Michelle Wood Waters Corporation, MS Technologies Centre, Manchester, UK ACQUITY UPLC I-Class/Xevo TQD 2 2 MRM 178 / 950 MS ACQUITY UPLC/ACQUITY TQD 2 1-3 MRM 100 LC/MS LC/MS 2 ACQUITY UPLC I-Class/Xevo TQD MRM 1-3 ACQUITY UPLC I-Class/Xevo TQD ACQUITY UPLC I-Class System Xevo TQD RADAR Technology PIC Scannning ACQUITY UPLC HSS C18 Waters UPLC /MS/MS 1

Sigma-Aldrich (Poole,Dorset,UK) LGC Standards(Teddington,Surrey,UK) 1 mg/ml Sigma-Aldrich Greyhound Chromatography(Brikenhead,UK) / Waters ACQUITY UPLC I-Class/Xevo TQD ACQUITY UPLC / TQD UPLC MS ACQUITY UPLC I-Class Xevo TQD A B ACQUITY UPLC HSS C18 2.1 x 150 mm 1.8 µm 186003534 50 10 5 µl MRM 10 µl 5 mm ph 3.0 5 mm ph 3.0 400 µl/min 5 mm ph 3.0 0.1% B 13% 95% 15 ESI ESI 3.0 kv 400 800 L/h 20 L/h MassLynx Multiple Reaction Monitoring MRM Targetlynx TM ChromaLynx TM ACQUITY TQD 1,2 ACQUITY UPLC 1,2 ACQUITY UPLC I-Class/Xevo TQD 2

FTN 5 ACQUITY UPLC I-Class 1 UPLC 100 µl RADAR PIC Xevo TQD 6 1 RADAR MRM Product Ion Confirmation scanning (PICs) MRM 1 ACQUITY UPLC I-Class/Xevo TQD MRM MS 178 MRM / 30 0.5 0.5 ACQUITY UPLC MRM ACQUITY UPLC I-Class ACQUITY UPLC I-Class/Xevo TQD 3

+20 V +35 V +50 V +65 V +80 V +95 V -20 V ChromaLynx 950 ACQUITY TQD Xevo TQD MRM SSM 2 ACQUITY UPLC I-Class/Xevo TQD SSM TargetLynx SSM 10 MRM 0.3 ACQUITY UPLC I-Class ACQUITY UPLC I-Class/Xevo TQD 4

Total Ion Chromatogram Library Spectrum Acquired Spectrum Candidate Listing 3 SSM ChromaLynx 10 MRM 1 0.19 ACQUITY UPLC I-Class methadone EDDP cocaine benzoylecgonine 4 ACQUITY UPLC I-Class/Xevo TQD MRM TargetLynx ACQUITY UPLC I-Class/Xevo TQD ACQUITY UPLC I-Class ACQUITY UPLC I-Class/Xevo TQD 5

ACQUITY UPLC/TQD (original configuration) ACQUITY UPLC I-Class/Xevo TQD (new configuration) RT RT RT Methadone 8.61 8.77 434734 8.80 463948 EDDP 7.46 7.67 145310 7.65 149118 Paracetamol 1.50 1.58 5703 1.55 55966 Cocaine 4.61 4.80 11644 4.75 11702 Benzoylecgonine 2.97 3.13 10500 3.09 11261 Nicotine 1.01 1.02 3284 1.05 6143 Caffeine 2.10 2.19 1499 2.16 3866 Temazepam 9.34 9.46 3683 Oxazepam 8.07 8.17 1853 8.18 2528 Theophylline 1.46 1.4 5 2255 Nordiazepam 9.14 9.31 1297 1 MRM 4 methadone TargetLynx ACQUITY UPLC I-Class/Xevo TQD 6

MRM 950 ChromaLynx 5 ACQUITY UPLC I-Class/Xevo TQD mirtazapine mirtazapine N-desmethyl ChromaLynx mirtazapine N-desmethyl ACQUITY TQD ACQUITY TQD Xevo TQD xylometazoline MRM 5 mirtazapine mirtazapine N-desmethyl ChromaLyn ACQUITY UPLC I-Class/Xevo TQD 7

PICs hydromorphone morphine Xevo TQD MRM Product Ion Confirmation scanning(pics) 6 MRM hydromorphone hydromorphone hydromorphone morphine MRM Hydromorphone morphine MRM 0.2 PIC PICs morphine hydromorphone TargetLynx hydromorphone morphine B A C 6 TargetLynx hydromorphone (A) 200 ng/ml hydromorphone (B) morphine (C) ACQUITY UPLC I-Class/Xevo TQD 8

RADAR RADAR MRM MRM RADAR MRM MRM RADAR MRM mirtazapine N-desmethyl desmethyl citalopram xylometazoline 3.79 6.47 7.42 8 2 30 V RADAR 7 RADAR MRM MRM mirtazapine N-desmethyl 3.79 desmethyl citalopram 6.47 xylometazoline 7.42 A B 8 RADAR mirtazapine N-desmethyl 3.79 (A) xylometazoline 7.42 (B) 30 V ACQUITY UPLC I-Class/Xevo TQD 9

UPLC/MS ACQUITY UPLC I-Class MS RADAR PICs Xevo TQD 1. Roberts M, Lee R, Wood M. Targeted MRM Screening for Toxicants in Biological Samples by UPLC/MS/MS. Waters Application Note 720002749EN. 2. Lee R, Roberts M, Paccou A, Wood M..Development of a New UPLC/MS Method for Systematic Toxicological Analysis. Waters Application Note 72002905EN. 3. Humbert L, Grisel F, Richeval C, Lhermitte M. Screening of Xenobiotics by Ultra-Performance Liquid Chromatography Mass Spectrometry Using In-Source Fragmentation at Increasing Cone Voltages: Library Constitution and an Evaluation of Spectral Stability. Journal of Analytical Toxicology. 2010; Vol. 34. 4. Rosano TG, Wood M, Swift TA. Postmortem Drug Screening by Non-Targeted and Targeted UltraPerformance Liquid Chromatography-Mass Spectrometry Technology. Journal of Analytical Toxicology. 2011; Vol. 35. 5. ACQUITY UPLC I-Class System Brochure. Waters Brochure 720003290EN. 6. Xevo TQD Brochure. Waters Brochure 720003953EN. www.waters.com 140-0001 1-3-12 5 TEL 03-3471-7191 FAX 03-3471-7118 532-0011 5-14-10 11F TEL 06-6304-8888 FAX 06-6300-1734 Waters ACQUITY UPLC ACQUITY UPLC PIC Xevo MassLynx Waters Corporation RADAR TargetLynx ChromaLynx The Science of What s Possible Waters Corporation 2013 Waters Corporation. Printed in Japan. 2013 6 720004602JA PDF